Drug Profile
P 128 - GangaGen
Alternative Names: P-128 - Gangagen; StaphTAMELatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator GangaGen
- Class
- Mechanism of Action Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Staphylococcal infections
- Preclinical Bacteraemia
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Staphylococcal-infections in USA (Topical)
- 22 Jun 2020 Preclinical trials in Staphylococcal infections in USA (IV) before June 2020
- 22 Jun 2020 Pharmacokinetics data from preclinical studies in Bacteraemia (including endocarditis due to staphylococcal infections) presented at the ASM Microbe Online 2020 (ASMM-2020)